A Position Paper on Preventive Therapies in the Fight Against AMR

The BEAM Alliance has released a new position paper, “Prevent Before You Treat: Accelerating Access to Preventive Therapies in the AMR Era”, highlighting the critical role of preventive therapies (PvTx) such as vaccines, immunotherapies, monoclonal antibodies, and decolonisation strategies in combating antimicrobial resistance (AMR).

The paper stresses that preventive approaches can save millions of lives by stopping infections before they occur. However, the paper also underscores major challenges to their development, including costly trials, regulatory fragmentation, and unclear clinical guidelines.

To address these barriers, BEAM calls for adapted regulatory pathways, including conditional approvals, the use of surrogate endpoints, and closer collaboration between developers and regulators. The Alliance urges policymakers to act swiftly, ensuring these life-saving innovations can reach vulnerable patients without compromising safety.

Read the full paper here